微RNAs (miRNAs) 在高血压中的作用:病原和有前途的治疗方法
Nour Shaheen1, Ahmed Shaheen1, Rehab Adel Diab2
1Faculty of Medicine, Alexandria University, Alexandria.
Annals of medicine and surgery (2012)
|January 15, 2024
概括
微RNAs (miRNAs) 是基本高血压的关键调节者. 研究表明miRNAs影响血压和心血管功能,为这种常见疾病提供潜在的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子遗传学 分子遗传学
- 在RNA生物学,RNA生物学.
背景情况:
- 微RNAs (miRNAs) 是小的,非编码RNAs调节细胞过程和疾病的发展.
- 新兴的研究表明,miRNAs与基本高血压的发病有关,这是一种普遍的心血管疾病.
- miRNAs通过准mRNA来控制蛋白质合成来调节心血管功能.
研究的目的:
- 审查当前对miRNA在基本高血压中的作用的理解.
- 探索在高血压中 miRNA 调节背后的分子机制.
- 讨论miRNAs在治疗高血压方面的治疗潜力.
主要方法:
- 对研究微RNA和基本高血压的研究进行文献综述.
- 对涉及心血管调节中mRNA的miRNA向分子机制的分析.
- 综合关于基于miRNA的高血压治疗策略的发现.
主要成果:
- 已经证明miRNAs可以调节对血管度,心脏功能和炎症至关重要的基因.
- 基于miRNA的疗法在调节高血压相关基因表达方面表现有前途.
- 有证据表明miRNAs可以改善血压和心血管功能.
结论:
- miRNAs在基本高血压的发展和进展中发挥着重要作用.
- 高血压中miRNA介导的机制需要进一步阐明.
- 针对miRNAs为新型高血压治疗提供了一个有希望的途径.
相关概念视频
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
Antihypertensive Drugs: Direct Renin Inhibitors
631
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
631
Antihypertensive Drugs: Angiotensin II Receptor Blockers
734
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
734


